Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial (Q51080505)
Jump to navigation
Jump to search
scientific article published on 27 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial |
scientific article published on 27 March 2017 |
Statements
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial (English)
1 reference
1 reference
1 reference
1 reference
Dirk Schadendorf
1 reference
Paolo A Ascierto
1 reference
Piotr Rutkowski
1 reference
Andrzej Mackiewicz
1 reference
Michele Del Vecchio
1 reference
Caroline Robert
1 reference
Vanna Chiarion-Sileni
1 reference
Céleste Lebbé
1 reference
Omid Hamid
1 reference
Catriona McNeil
1 reference
Claus Garbe
1 reference
Carmen Loquai
1 reference
Brigitte Dreno
1 reference
Luc Thomas
1 reference
Jean-Jacques Grob
1 reference
Gabriella Liszkay
1 reference
Marta Nyakas
1 reference
Ralf Gutzmer
1 reference
Joanna Pikiel
1 reference
Florent Grange
1 reference
Christoph Hoeller
1 reference
Michael Smylie
1 reference
Laurent Mortier
1 reference
Delphine Hennicken
1 reference
Anila Qureshi
1 reference
27 March 2017
1 reference
18
1 reference
5
1 reference
611-622
1 reference